AACR 2026 Preview: Over 400 Studies and 92 ADCs Signal a “Qualitative Leap” for China’s Innovative Drug Industry

Against the backdrop of rapidly advancing global oncology research, AACR 2026 has become a focal point for the industry. Based on currently available information, the conference will present more than 400 research studies, including as many as 92 projects related to antibody-drug conjugates (ADCs). This figure not only reflects the explosive growth of ADC technology but also signals a profound shift in the competitive landscape of innovative drugs. Meanwhile, the increased participation of Chinese innovative pharmaceutical companies at this year’s event highlights a transition from “quantitative accumulation” to “qualitative transformation.”

In this context, AACR 2026 is not only an academic gathering but also a key window into global trends in innovative drug development.

ADC Boom Continues: From Hotspot to Refined Competition

In recent years, ADCs have emerged as one of the most closely watched technologies in oncology by both capital markets and the pharmaceutical industry. From a handful of early success stories to today’s large-scale clinical deployment, ADCs are evolving from “frontier exploration” to “mainstream competition.”

At AACR 2026, the record-high number of ADC-related studies reflects several key developments:

●  Continuous technological iteration, with ongoing optimization of linkers and payloads

●  Expansion of targets beyond traditional HER2 to broader solid tumors and emerging biomarkers

●  Increasing adoption of combination therapies to enhance efficacy

It is evident that the ADC field is no longer about whether the technology exists, but rather about who can execute it better. Companies that succeed will likely possess strong platform-based R&D capabilities and differentiated design strategies.

This trend also suggests that the ADC space is transitioning from rapid expansion to structural differentiation.

Convergence of Technologies: Oncology Enters a Systems-Based Era

While ADCs remain a major highlight, AACR 2026 also reveals a broader shift in oncology treatment paradigms. The research landscape suggests that single-modality therapies are increasingly being replaced by multi-technology integration.

A new R&D logic is emerging—combining different mechanisms to enhance overall therapeutic outcomes. Examples include:

●  Immunotherapy combined with anti-angiogenic treatments

●  Synergistic use of ADCs with immunotherapies

●  Biomarker-driven precision stratification approaches

This shift indicates that future competition in innovative drugs will become more complex. Companies must not only excel in individual technologies but also demonstrate the ability to integrate multiple therapeutic approaches.

Over the long term, this “system-based treatment model” is expected to become a defining trend in oncology.

Rise of Chinese Innovators: From Participants to Competitors

Chinese pharmaceutical companies are drawing significant attention at AACR 2026. Both the number of projects and the depth of research demonstrate notable progress.

Over the past few years, China’s innovative drug sector has experienced rapid growth:

●  Continuous increase in clinical-stage pipelines

●  Growing number of international collaborations and licensing deals

●  Gradual shift from follow-on innovation to first-in-class research

However, the industry is now entering a new phase. Market expectations have shifted from “quantity” to “quality.” Companies are now required to demonstrate:

●  Genuine clinical value

●  Global competitiveness

●  Commercialization capabilities

In this evolving environment, Chinese innovators are moving beyond homogeneous competition toward differentiation and globalization. This transformation represents the essence of the industry’s “qualitative leap.”

Global Expansion Deepens: Supply Chain as a Critical Enabler

As Chinese innovative drug capabilities strengthen, global expansion is no longer optional—it has become essential. Companies are transitioning from early-stage licensing (License-out) to independently advancing global clinical programs.

True globalization, however, requires more than exporting products. It depends on comprehensive system capabilities, including:

●  R&D and clinical systems aligned with international standards

●  Manufacturing and quality systems compliant with global regulations

●  Efficient and resilient global supply chain networks

In this context, the importance of supply chains continues to grow. With increasingly stringent cross-border compliance requirements, companies with strong global resource integration capabilities are becoming key enablers of international expansion.

For example, Dengyue Pharma plays a role in integrating international pharmaceutical resources and distribution networks, providing compliant and efficient cross-border supply solutions. By bridging R&D outcomes and global markets, such platforms enhance drug accessibility and support the commercialization of innovative therapies.

Industry Outlook: Toward Rational and Sustainable Growth

Signals from AACR 2026 suggest that the global innovative drug industry is entering a new development cycle. Compared to the previous phase of rapid expansion, the current stage emphasizes quality, efficiency, and sustainability.

Key future trends may include:

●  Continued advancement of high-barrier technologies such as ADCs

●  Multi-technology integration as the dominant R&D paradigm

●  Intensifying global competition

●  Increasing importance of supply chain collaboration

In this evolving landscape, competitive differentiation will depend more on systemic capabilities than on single technological breakthroughs.

AACR 2026 highlights not only the rapid advancement of innovative drug technologies but also a fundamental shift in industry dynamics. From the continued rise of ADCs to the integration of multiple therapeutic modalities and the emergence of Chinese innovators, the global pharmaceutical landscape is entering a new era.